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This is one of a series of BMJ summaries of new guidelines based on
the best available evidence; they highlight important recommendations
for clinical practice, especially where uncertainty or controversy exists.
Melanoma is the fifth most common cancer in the United
Kingdom, with more than 13 000 cases diagnosed in 2011 and
its incidence is rising rapidly.1 Clinical practice seems to vary
in the UK, especially with regard to the use of dermoscopy and
photography, access to sentinel lymph node biopsy, vitamin D
measurement and advice, follow-up policies, and the use of
routine follow-up imaging. Patient groups have reported
inadequate information on management options.
This article summarises the most important recent
recommendations from the National Institute for Health and
Care Excellence (NICE) on the diagnosis and care of people
with melanoma.2
Recommendations
NICE recommendations are based on systematic reviews of the
best available evidence and explicit consideration of cost
effectiveness. When minimal evidence is available,
recommendations are based on the guideline development
group’s experience and opinion of what constitutes good
practice. Evidence levels for the recommendations are given in
italics in square brackets. The recommendations specifically
apply to secondary and tertiary care locations, where these
patients should all be managed by specialist multidisciplinary
teams (MDTs), but they will also affect the management of
patients with melanoma in primary care.
The staging of melanoma is detailed and complex and the full
staging system is available online.3 The brief explanations of
stage given may not be precise and are there to help make the
context of the recommendation clearer.
Communication and support
• To help people make decisions about their care, follow the
recommendations on communication, information
provision, and support in the NICE guideline on improving
outcomes for people with skin tumours including
melanoma.4 [Based on low to high quality evidence from
observational studies and on the experience and opinion
of the guideline development group (GDG).]
Assessing melanoma
• Assess all pigmented skin lesions that are referred for
assessment or identified during follow-up using
dermoscopy carried out by healthcare professionals trained
in this technique. Do not routinely use confocal microscopy
or computer assisted diagnostic tools. [Based on moderate
quality evidence from diagnostic studies.]
Photography
• For a clinically atypical melanocytic lesion that does not
need excision at first presentation use baseline photography
(preferably dermoscopic). Also use this technique to review
the clinical appearance of the lesion three months after first
presentation to identify early signs of melanoma [Based
on low to moderate quality evidence from diagnostic
studies.]
Taking tumour samples for genetic testing
With the advent of effective treatments for people with
metastatic disease, genetic testing of tumour samples for driver
mutations (such as BRAF), which determine the likelihood of
response to therapy, is becoming more important. For those
who are being considered for systemic therapy:
• Offer genetic testing using a secondary (metastatic)
melanoma tissue sample or a primary melanoma tissue
sample if a secondary sample is not available or is of
inadequate cellularity. [Based on moderate to high quality
evidence from diagnostic studies.]
However:
• Do not offer genetic testing of stages IA-IIB primary
melanoma (≤4 mm thick with ulceration or >4 mm thick
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• Use dermoscopy to examine all pigmented lesions referred for assessment and ensure that all staff are adequately trained in its use
• Consider sentinel node biopsy as a staging tool for patients with stage II melanoma and stage 1B melanoma thicker than 1 mm. Use
box 1 or the options grid being developed to discuss the potential advantages and disadvantages of the procedure with patients
• If a sentinel node biopsy is positive for melanoma, discuss the potential advantages and disadvantages of completion lymphadenectomy
with the patient using box 2 or the options grid being developed
• Consider regular imaging in patients at greater risk of progression to stage IV (metastatic) melanoma. Use box 3 or the options grid
being developed to discuss potential advantages and disadvantages of this with the patient
How patients were involved in the creation of this article
Committee members involved in this guideline update included lay members who contributed to the formulation of the recommendations
summarised here. Patient and carer organisations were among the stakeholders who commented on the draft guideline.
with no ulceration, no spread) at presentation except as
part of a clinical trial. [Based on the experience and opinion
of the GDG.]
• For stage IIC primary melanoma (>4 mm thick, no spread,
ulcerated), consider genetic testing. [Based on the
experience and opinion of the GDG.]
• For stage III melanoma (spread to lymph nodes or the
cutaneous or subcutaneous lymphatics proximal to those
nodes—“in transit” metastases), consider testing metastatic
tissue; if insufficient material is available, genetic testing
of the primary tumour may be necessary. [Based on the
experience and opinion of the GDG.]
Managing suboptimal vitamin D levels
Many people withmelanoma have suboptimal levels of vitamin
D at diagnosis but are usually advised to avoid sun exposure to
reduce the risk of further melanomas. Vitamin D is important
for bone health and possibly for other aspects of health, so
further reduction in levels should be avoided. The guideline
also suggests avoiding high levels as a result of unnecessary
supplementation.
• Measure vitamin D levels at diagnosis in all people with
melanoma.
• For people whose vitamin D levels are thought to be
suboptimal, provide advice on supplementation and
monitoring in line with local policies and the NICE
guideline on vitamin D.5 [Based on moderate to very low
quality evidence from observational studies.]
Staging investigations
The role of sentinel lymph node biopsy (SLNB) is controversial,
with its routine use varying greatly across England and Wales.
Not all people routinely need imaging at diagnosis:
• Do not offer imaging or SLNB to people who have stage
I melanoma with a Breslow thickness of 1 mm or less.
[Based on very low to high quality evidence from
observational studies and on the experience and opinion
of the GDG.]
• Consider SLNB as a staging rather than a therapeutic
procedure for people with stages IB-IIC melanoma with a
Breslow thickness of more than 1 mm, and give these
people detailed verbal and written information about the
possible advantages and disadvantages (see box 1). [Based
on very low to high quality evidence from observational
studies and cost effectiveness analysis.]
• Offer computed tomography staging to people with stage
IIC melanoma who have not had SLNB and to people with
stage III (lymph nodes or in transit spread) or suspected
stage IV melanoma (distant metastases). Include imaging
of the brain for people with suspected stage IV melanoma.
[Based on very low to high quality evidence from
observational studies and on the experience and opinion
of the GDG.]
• Consider whole body magnetic resonance imaging for
children and young people (from birth to 24 years) with
stage III or suspected stage IV melanoma. [Based on very
low to high quality evidence from observational studies
and on the experience and opinion of the GDG.]
Managing stages 0-II melanoma
With regard to excision margins:
• Consider a clinical margin of at least 0.5 cmwhen excising
stage 0 melanoma (in situ), but if excision does not achieve
an adequate histological margin, discuss further
management with theMDT. [Based on low quality evidence
from randomised trials.]
• Offer excision with a clinical margin of at least 1 cm to
people with stage I (≤2 mm thick) and of at least 2 cm to
people with stage II melanoma (1.01-2 mm thick if
ulcerated or >2 mm thick). [Based on low quality evidence
from randomised trials.]
Managing stage III melanoma (lymph nodes
or in transit spread)
There is controversy and practice variation about the
management of involved lymph nodes found at SLNB, by
imaging, or at clinical examination.
• Consider completion lymphadenectomy (removing residual
local lymph nodes) for people whose SLNB shows
micrometastases and give them detailed verbal and written
information about the possible advantages and
disadvantages (see box 2). [Based on very low quality
evidence from observational studies.]
• Offer therapeutic lymph node dissection to people with
palpable stages IIIB-IIIC nodal melanoma or nodal disease
detected by imaging. [Based on very low quality evidence
from observational studies.]
• Do not offer adjuvant radiotherapy to people with stage
IIIA disease or to those with stage IIIB or IIIC melanoma
unless a reduction in the risk of local recurrence is
estimated to outweigh the risk of serious adverse effects.
[Based on very low quality evidence from observational
studies.]
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Box 1: Possible advantages and disadvantages of sentinel lymph node biopsy (SLNB)
Advantages
SLNB helps to find out whether the cancer has spread to the lymph nodes and is better than ultrasound scans at finding very small
cancers in the lymph nodes
It can help predict what might happen in the future. For example, in people with a 1-4 mm thick primary melanoma, about one in 10 dies
within 10 years if SLNB is negative; about three in 10 die if SLNB is positive
People who have had SLNB may be able to take part in clinical trials of new treatments for melanoma. These trials often cannot accept
people who haven’t had this operation
Disadvantages
The purpose of SLNB is not to cure the cancer. There is no good evidence that people who have the operation live longer than those
who do not have it
The result needs to be interpreted with caution. For every 100 people with a negative SLNB result, about three will develop a recurrence
in the same group of lymph nodes
The operation requires a general anaesthetic
The procedure results in complications such as deep venous thrombosis, seromas, or wound infections in 4-10 of every 100 people
Box 2: Possible advantages and disadvantages of completion lymphadenectomy
Advantages
Removing the rest of the lymph nodes before cancer develops in them reduces the chance of the cancer returning in the same part of
the body
The operation is less complicated and safer than waiting until cancer develops in the remaining lymph nodes and then removing them
People who have had the operation may be able to take part in clinical trials of new treatments to prevent future melanoma. These trials
often cannot accept people who have not had this operation
Disadvantages
Lymphoedema (long term swelling) may develop; it is more likely if the operation is in the groin and least likely in the head and neck
In four out of five people, cancer will not develop in the remaining lymph nodes, so there is a chance that the operation will have been
done unnecessarily
There is no evidence that people who have this operation live longer than those who do not have it
Having any operation can cause complications
Managing stage IV melanoma (distant
metastases)
Many patients with metastases will be treated with targeted
therapy in line with NICE guidance on dabrafenib, ipilimumab
and vemurafenib.6-9 However, some situations require separate
advice:
• Refer the care of people with oligometastases (metastases
of limited extent, for which ablation or surgery may be
feasible) to the specialist skin cancer MDT for
recommendations about staging and management. [Based
on very low quality evidence from observational studies.]
• Consider surgery or other ablative treatments (including
stereotactic radiotherapy or radioembolisation) to prevent
and control symptoms in consultation with site specific
MDTs (such as MDTs for the brain or bones). [Based on
very low quality evidence from observational studies.]
• Discuss the care of people with melanoma and brain
metastases with the specialist skin cancer MDT. [Based
on the experience and opinion of the GDG.]
• Refer people with melanoma and brain metastases that
might be suitable for surgery or stereotactic radiotherapy
to the brain and other central nervous system tumoursMDT
for a recommendation about treatment. [Based on the
experience and opinion of the GDG.]
Cytotoxic chemotherapy may be indicated for patients who are
unsuitable for targeted systemic therapies:
• Consider dacarbazine for people with stage IV metastatic
melanoma if immunotherapy or targeted therapy is not
suitable. [Based on high quality evidence from randomised
trials and cost effectiveness evidence.]
• Do not routinely offer further cytotoxic chemotherapy for
stage IVmetastatic melanoma to people previously treated
with dacarbazine except in the context of a clinical trial.
[Based on high quality evidence from randomised trials.]
Follow-up after treatment for melanoma
• All local follow-up policies should include reinforcing
advice about self examination as well as health promotion
for people with melanoma and their families, including sun
awareness while avoiding vitamin D depletion (in line with
local policies and the NICE guideline on vitamin D),5 and
smoking cessation. [Based on very low quality evidence
from observational studies and on the experience and
opinion of the GDG.]
• Discharge people who have had stage 0 melanoma after
completing treatment. [Based on very low quality evidence
from observational studies and on the experience and
opinion of the GDG.]
• For those with stage IA melanoma (≤1 mm thick, no
spread, no ulceration, no mitoses), consider follow-up two
to four times during the first year after completing treatment
and discharge at the end of that year. Do not routinely offer
screening investigations (including imaging and blood
tests) as part of follow-up. [Based on very low quality
evidence from observational studies and on the experience
and opinion of the GDG.]
• For those with stages IB-IIB melanoma (any thickness if
not ulcerated, up to 4 mm thick if ulcerated, no spread) or
stage IIC melanoma (>4 mm thick, ulcerated, no spread)
with a negative SLNB, consider follow-up every three
months for the first three years after completing treatment,
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then every six months for the next two years and discharge
at the end of five years. Do not routinely offer screening
investigations (including imaging and blood tests) as part
of follow-up. [Based on very low quality evidence from
observational studies and on the experience and opinion
of the GDG.]
• For people who have had stage IICmelanoma but no SLNB
or stage III (involved lymph nodes) melanoma, consider
follow-up every three months for the first three years after
completion of treatment, then every six months for the next
two years, and discharge at the end of five years. [Based
on very low quality evidence from observational studies,
cost effectiveness analysis, and the experience and opinion
of the GDG.]
• For people who have had stage IIC melanoma, but no
SLNB, or stage III melanoma, and who would become
eligible for systemic therapy as a result of early detection
of metastatic disease, consider surveillance imaging as part
of follow-up if there is a clinical trial of the value of regular
imaging or if the specialist skin cancer MDT agrees to a
local policy and specific funding for imaging six monthly
for three years is identified. Discuss the possible advantages
and disadvantages of surveillance imaging (box 3) with
the person. [Based on very low quality evidence from
observational studies, a cost effectiveness analysis, and
the experience and opinion of the GDG.]
• For people who have had stage IV (distant metastases)
melanoma, offer personalised follow-up. [Based on very
low quality evidence from observational studies and on the
experience and opinion of the GDG.]
Overcoming barriers
Dermoscopy is not routinely used in all clinics where pigmented
lesions are assessed, so equipment will need to be purchased
and staff trained. Vitamin D is rarely measured and there is
uncertainty about how best to manage suboptimal levels. New
guidance from the Scientific Advisory Committee on Nutrition
(SACN) expected in 2015 will be helpful. Not all MDTs offer
SLNB and some that do reportedly do not always offer the
choice of not having it. Change is needed both in how this is
discussed with patients and in its provision where it is currently
unavailable.
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Box 3: Possible advantages and disadvantages of follow-up imaging
Advantages
Early detection of recurrence may allow people to receive treatment with drugs such as immunotherapeutic agents earlier than they
would otherwise, which might lead to better outcomes
Some patients find it reassuring to have regular scans
Disadvantages
There is currently no evidence that treating recurrent melanoma earlier increases the probability of a better outcome
Having regular scans may increase some people’s anxiety, even though for many, no recurrence will ever occur
Regular scans increase the body’s exposure to radiation, which itself increases the risk of second cancers later in life. For example,
imaging of the chest results in a very small increase in the risk of thyroid cancer
Imaging of the brain and neck results in a small increase in the risk of developing cataracts
Incidental abnormalities of no clinical significance that require further investigations might be identified, and this may cause anxiety until
the situation is resolved
Further information on the guidance
Methods
This guidance was developed by the National Collaborating Centre for Cancer using current NICE guideline methodology (www.nice.org.
uk/guidelinesmanual). The guidance review process involved literature searches to identify relevant evidence, with critical appraisal of the
quality of the identified evidence. A multidisciplinary team of service users, carers, and healthcare professionals (including dermatologists,
surgeons, clinical and medical oncologists, a general practitioner, a histopathologist, a radiologist, clinical nurse specialists, and patient and
carer representatives)—the guideline development group (GDG)—was established to review the evidence and develop the subsequent
recommendations. The guidance then went through an external consultation with stakeholders. The GDG considered the stakeholders’
comments, reanalysed the data where necessary, and modified the guidance as appropriate.
NICE has produced three different versions of the guidance: a full version; a summary version known as the “NICE guidance”; and a version
for people using NHS services, their families, and carers (www.nice.org.uk/guidance/ng14/informationforpublic), and the public. All these
versions are available from the NICE website (www.nice.org.uk/guidance/ng14). Further updates of the guidance will be produced as part
of NICE’s guideline development programme. Implementation tools are available at www.nice.org.uk/guidance/ng14/resources.
Future research
Based on its review of evidence, the GDG has made the following recommendations for research to improve NICE guidance and patient
care in the future:
• In people with reported atypical spitzoid lesions, how effective are fluorescence in situ hybridization, comparative genomic hybridisation,
and tests to detect driver mutations compared with histopathological examination alone in predicting disease specific survival?
• For people with lentigo maligna (stage 0 in sun damaged skin, usually on the face), how effective is Mohs micrographic surgery,
compared with excision with a 0.5 cm clinical margin, in preventing biopsy confirmed local recurrence at five years?
• In people treated for high risk stages II and III melanoma, does regular surveillance imaging improve melanoma specific survival
compared with routine clinical follow-up alone?
• In people with stages I-III melanoma, does vitamin D supplementation improve overall survival?
• In people diagnosed as having melanoma, what is the effect of drug therapy to treat concurrent conditions on disease specific survival?
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